drcampos
★    

Brazil,
2007-07-25 19:21
(6491 d 23:40 ago)

Posting: # 940
Views: 5,348
 

 truncated AUC [NCA / SHAM]

Post reply
Dear Helmut,

Articles and Guidances have said that the use of truncated area under the curve could be a significant advantage for BE studies of drugs with long half-lives and low intrasubject variability. So, I would like to know why is not truncated AUC a good option to high intrasubject variability drug?

Regards,

Daniel Rossi de Campos
Brazil
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2007-07-25 19:39
(6491 d 23:22 ago)

@ drcampos
Posting: # 941
Views: 4,174
 

 truncated AUC

Post reply
Dear Daniel,

I don’t see any reason why a truncated AUC should not be applied for a HVD/HVDP.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
172 visitors (0 registered, 172 guests [including 5 identified bots]).
Forum time: 19:02 CEST (Europe/Vienna)

If you tell the truth you don’t have to remember anything.    Mark Twain

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5